Whole-Exome Sequencing of Metastatic Cancer and Biomarkers of Treatment Response.

doi:10.1001/jamaoncol.2015.1313

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Whole-Exome Sequencing of Metastatic Cancer and Biomarkers of Treatment Response.

JAMA oncology - 1 Jul 2015

Beltran Himisha, Eng Kenneth, Mosquera Juan Miguel, Sigaras Alexandros, Romanel Alessandro, Rennert Hanna, Kossai Myriam, Pauli Chantal, Faltas Bishoy, Fontugne Jacqueline, Park Kyung, Banfelder Jason, Prandi Davide, Madhukar Neel, Zhang Tuo, Padilla Jessica, Greco Noah, McNary Terra J, Herrscher Erick, Wilkes David, MacDonald Theresa Y, Xue Hui, Vacic Vladimir, Emde Anne-Katrin, Oschwald Dayna, Tan Adrian Y, Chen Zhengming, Collins Colin, Gleave Martin E, Wang Yuzhuo, Chakravarty Dimple, Schiffman Marc, Kim Robert, Campagne Fabien, Robinson Brian D, Nanus David M, Tagawa Scott T, Xiang Jenny Z, Smogorzewska Agata, Demichelis Francesca, Rickman David S, Sboner Andrea, Elemento Olivier, Rubin Mark A

Abstract excerpt

IMPORTANCE: Understanding molecular mechanisms of response and resistance to anticancer therapies requires prospective patient follow-up and clinical and functional validation of both common and low-frequency mutations. We describe a whole-exome sequencing (WES) precision medicine trial focused on patients with advanced cancer. OBJECTIVE: To understand how WES data affect therapeutic decision making in patients...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Academic Medical Centers

Share to Feasibility Studies

Share to INDEL Mutation

Share to Molecular Targeted Therapy

Share to Neoplasm Metastasis

Share to Patient Selection

Share to Precision Medicine

Share to Xenograft Model Antitumor Assays

Source

Open in PubMed Open full text

Identifiers

PMID: 26181256
DOI: 10.1001/jamaoncol.2015.1313
PMCID: PMC4505739

Genes

FANCA

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Whole-Exome Sequencing of Metastatic Cancer and Biomarkers of Treatment Response.PMID 26181256Read ↗

Next-generation sequencing-based evaluation of the actionable landscape of genomic alterations in solid tumors: the "MOZART" prospective observational study.Semantic proximity Read ↗

Advances in Precision Oncology: From Molecular Profiling to Regulatory-Approved Targeted TherapiesSemantic proximity Read ↗

Comparison of actionable events detected in cancer genomes by whole-genome sequencing, in silico whole-exome and mutation panels.Semantic proximity Read ↗

Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients.Semantic proximity Read ↗

Integrative Molecular Analysis of Patients With Advanced and Metastatic CancerSemantic proximity Read ↗

Next-Generation Sequencing-Based Evaluation of the Actionable Mutational Landscape in Solid Tumors: the “MOZART” Prospective Observational StudySemantic proximity Read ↗

Discovery and reporting of clinically-relevant germline variants in advanced cancer patients assessed using whole-exome sequencingSemantic proximity Read ↗

Personalized genomic analyses for cancer mutation discovery and interpretation.Semantic proximity Read ↗

Implementation and use of whole exome sequencing for metastatic solid cancer.Semantic proximity Read ↗

Use of a Targeted Exome Next-Generation Sequencing Panel Offers Therapeutic Opportunity and Clinical Benefit in a Subset of Patients With Advanced CancersSemantic proximity Read ↗

Single whole genome sequencing analysis blazes the trail for precision medicine.Semantic proximity Read ↗

Pan-cancer whole-genome analyses of metastatic solid tumours.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.